Proteomics nears launch of groundbreaking muscle stress test
Muscle lesions are often guided by oxidative stress. They represent up to 55 % of all sports injuries, which is estimated that they cost Australian $ 1.2 billion per year. The numbers are no less disconcerting in the horse racing sector, given a huge 85 % of thoroughbreds collected at least one injury in their early years.
Oxidx is one of the numerous blood tests that the proteomic has in development or is launching in some potentially very profitable health markets.
The company has also recently been committed to launching its revolutionary predictive promarkerd diagnostic test in Australia and the United States, which provides an early warning sign for chronic renal disease in people with type 2 diabetes. Clinical studies show that Promarkerd can provide the condition of up to four years before hitting, opening the door to the diagnosis and treatment previous for patients at risk.
With over 500 million diabetics worldwide, Proteomics International sees enormous global potential for Promarkerd. The company aims to position the test as a serious contender to become the diagnostic tool for the prevention of kidney diseases.
With sporting technology, equine health and wider clinical applications in its eyes and patents blocked in position for the long -haul Proteomics Oxidx test could be galloped towards a considerable slice of a diagnostic market of billions of dollars.
Is your company listed in Asx doing something interesting? Contact: matebirney@bullsnbears.com.au
